- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: AIDS-Related Lymphoma - January 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de enero del 2002
Table of Contents
1
UI - 11450910
AU - Lee AG; Tang RA; Roberts D; Schiffman JS; Osborne A
TI -
Primary central nervous system lymphoma involving the optic chiasm in
AIDS.
SO - J Neuroophthalmol 2001 Jun;21(2):95-8
AD - Department of Ophthalmology, The University of Iowa Hospitals and
Clinics, Iowa City 52242, USA. andrew-lee@uiowa.edu
OBJECTIVE: To report visual loss resulting from chiasmal involvement by
primary central nervous system lymphoma (PCNSL). MATERIALS AND METHODS:
Case report. RESULTS: A patient with the acquired immune deficiency
syndrome (AIDS) presented with visual loss resulting from PCNSL
involving the optic chiasm. The clinical findings, neuroimaging,
pathology, and treatment of this patient are described. CONCLUSIONS:
Although rare, clinicians should consider PCNSL in the differential of a
hypothalamic/chiasmal mass, especially in a patient with AIDS.
2
UI - 11573962
AU - Sun Y; Huang PL; Li JJ; Huang YQ; Zhang L; Huang PL; Lee-Huang S
TI -
Anti-HIV agent MAP30 modulates the expression profile of viral and
cellular genes for proliferation and apoptosis in AIDS-related lymphoma
cells infected with Kaposi's sarcoma-associated virus.
SO - Biochem Biophys Res Commun 2001 Oct 5;287(4):983-94
AD - Department of Biochemistry, New York University School of Medicine, New
York, NY 10016, USA.
The anti-HIV agent MAP30 (Momordica anti-HIV protein, 30 kDa) inhibits
the proliferation of BC-2, an AIDS-related primary effusion lymphoma
(PEL) cell line derived from an AIDS patient. BC-2 cells are latently
infected with Kaposi's sarcoma-associated herpes virus (KSHV), also
known as human herpes virus 8 (HHV8). We examined the effect of MAP30 on
the expression of viral and cellular genes in BC-2 during latent and
lytic states of the viral life cycle. By Northern analysis and RT-PCR,
we found that MAP30 downregulates the expression of viral cyclin D
(vCD), viral interleukin-6 (vIL-6), and viral FLIP (vFLIP), genes
involved in cell cycle regulation, viral pathogenesis, and apoptosis. By
pathway-specific cDNA microarray analysis, we found that BC-2 cells
express high levels of egr-1, ATF-2, hsp27, hsp90, IkappaB, mdm2, skp1,
and IL-2, cellular genes involved in mitogenesis, tumorigenesis, and
inhibition of apoptosis in NFkappaB and p53 signaling pathways. These
results define for the first time the specific cellular pathways
involved in AIDS-related tumorigenesis and suggest specific novel
targets for the treatment. Furthermore, we found that MAP30
downregulates the expression of egr-1, ATF-2, hsp27, hsp90, IkappaB,
mdm2, and Skp1, while it upregulates the pro-apoptotic-related genes
Bax, CRADD, and caspase-3. Thus, MAP30 modulates the expression of both
viral and cellular genes involved in KS pathogenesis. These results
provide valuable insight into the molecular mechanisms of MAP30 anti-KS
action and suggest its utility as a therapeutic agent against
AIDS-related tumors. Copyright 2001 Academic Press.
3
UI - 11577180
AU - Gallia GL; DelValle L; Laine C; Curtis M; Khalili K
TI -
Concomitant progressive multifocal leucoencephalopathy and primary
central nervous system lymphoma expressing JC virus oncogenic protein,
large T antigen.
SO - Mol Pathol 2001 Oct;54(5):354-9
AD - Center for NeuroVirology and Cancer Biology, College of Science and
Technology, Temple University, 1900 North 12th Street, Room 203,
Philadelphia, PA 19122, USA.
This report describes the concomitant occurrence of the JC virus (JCV)
induced demyelinating disease progressive multifocal leucoencephalopathy
(PML) and a primary central nervous system lymphoma (PCNS-L) in a
patient with AIDS. Postmortem neuropathological examination revealed
characteristic features of PML including multiple lesions of
demyelination, enlarged oligodendrocytes with hyperchromatic nuclei
(many containing eosinophilic intranuclear inclusions), and enlarged
astrocytes with bizarre hyperchromatic nuclei. Immunohistochemical
analysis demonstrated the expression of the JCV capsid protein VP-1 in
the nuclei of infected oligodendrocytes and astrocytes. The PCNS-L
lesion located in the basal ganglia was highly cellular, distributed
perivascularly, and consisted of large atypical plasmacytoid
lymphocytes. Immunohistochemical examination of this neoplasm identified
it to be of B cell origin. Moreover, expression of the JCV oncogenic
protein, T antigen, was detected in the nuclei of the neoplastic
lymphocytes. This study provides the first evidence for a possible
association between JCV and PCNS-L.
4
UI - 11578578
AU - Gallardo FG; Moreno V; Babe J; Cobo J; Rios M; Gomez MV
TI -
[Brain SPECT with 201-thallium in AIDS patients]
SO - Rev Esp Med Nucl 2001 Oct;20(6):439-42
AD - Servicio de Medicina Nuclear.Hospital Carlos III, Madrid, Spain.
fgonzalez@hciii.insalud.es
Brain lymphoma is a late complication in AIDS. Lymphoma incidence is
increasing in AIDS patients due to the introduction of HAART and
prolongation of these patients' life expectancy. This work aims to
evaluate the usefulness of brain SPECT with 201Tl in patients with AIDS
who present focal brain lesions in computed tomography (CT).Methods:
Seventeen patients with neurologic symptoms and focal neurologic lesions
in the CNS (central nervous system) were studied. The images were
interpreted as positive when the intensity of the focal deposit of the
tracer was greater than that of the adjacent tissue. The SPECT results
were compared with serologic data, clinical evolution and/or radiologic
follow-up and cerebral biopsy.Results: SPECT images showed focal uptake
of radiotracer in 3 patients. All three died shortly after the SPECT was
performed. All of them had negative serology for toxoplasmosis. Four
patients were diagnosed of progressive multifocal leukoencephalopathy
and the ten remaining cases had a good clinical and/or radiologic
response.Conclusions: Brain SPECT with 201Tl is a very useful
non-invasive technique for the differential diagnosis of cerebral focal
lesions in AIDS patients.
5
UI - 11588028
AU - Besson C; Goubar A; Gabarre J; Rozenbaum W; Pialoux G; Chatelet FP;
TI -
Katlama C; Charlotte F; Dupont B; Brousse N; Huerre M; Mikol J; Camparo
P; Mokhtari K; Tulliez M; Salmon-Ceron D; Boue F; Costagliola D; Raphael
M
Changes in AIDS-related lymphoma since the era of highly active
antiretroviral therapy.
SO - Blood 2001 Oct 15;98(8):2339-44
AD - Hopital Necker, SC4-INSERM, CHU Pitie Salpetriere, Hopital Rothschild,
Paris, France. caroline.besson@nck.ap-hop-paris.fr
HIV infection is associated with a high incidence of AIDS-related
lymphomas (ARLs). Since the use of highly active antiretroviral therapy
(HAART), the incidence of AIDS-defining illnesses has decreased, leading
to a significant improvement in survival of HIV-infected patients. The
consequences of HAART use on ARL are under debate. This study compared
the incidence and the characteristics of ARL before and after the use of
HAART in a large population of HIV-infected patients in the French
Hospital Database on HIV (FHDH) and particularly in 3 centers including
145 patients with proven lymphoma. Within the FHDH, the incidence of
systemic ARL has decreased between 1993-1994 and 1997-1998, from 86.0
per 10 000 to 42.9 per 10 000 person-years (P < 10(-30)). The incidence
of primary brain lymphoma has also fallen dramatically between the
periods, from 27.8 per 10 000 to 9.7 per 10 000 person-years (P <
10(-11)). The analysis of 145 cases of ARL in 3 hospitals showed that
known HIV history was longer in the second period than in the first
period among patients with systemic ARL (98 versus 75 months; P <.01).
Patients had a higher number of CD4 cells at diagnosis during the second
period (191 versus 63/microL, P = 10(-3)). Survival of patients with
systemic ARL also increased between the periods (from 6 to 20 months; P
=.004). Therefore, the profile of ARL has changed since the era of
HAART, with a lower incidence of systemic and brain ARL. The prognosis
of systemic ARL has improved.
6
UI - 11588031
AU - Seneviratne L; Espina BM; Nathwani BN; Chan JA; Brynes RK; Levine AM
TI -
Clinical, immunologic, and pathologic correlates of bone marrow
involvement in 291 patients with acquired immunodeficiency
syndrome-related lymphoma.
SO - Blood 2001 Oct 15;98(8):2358-63
AD - Department of Medicine, Keck School of Medicine, University of Southern
California, Los Angeles 90033, USA.
Bone marrow involvement is reported in approximately 25% of patients
with newly diagnosed acquired immunodeficiency syndrome-related lymphoma
(ARL). Studied were 291 patients with ARL, diagnosed and treated at one
medical center between 1984 and 1998. Clinical, immunologic, and
pathologic characteristics of patients with bone marrow involvement were
compared with those of patients without marrow involvement. Bone marrow
involvement was present in 55 patients (19%). Small noncleaved lymphoma
was diagnosed in 38% of the entire group and was the most common
pathologic subtype in patients with bone marrow involvement (55% versus
34%; P =.008). Analysis of complete blood counts revealed a median
hemoglobin level of 10.6 g/dL in both marrow-positive and
marrow-negative groups. In contrast, a platelet count lower than 100
000/microL was more common in patients with bone marrow involvement (27%
versus 11%; P =.02). Patients with marrow involvement were more likely
to have leptomeningeal (cerebrospinal fluid [CSF]) lymphoma than
patients whose marrows were uninvolved (24% versus 7%; P <.001) and were
also more likely to have high lactate dehydrogenase (LDH) (P =.002),
bone involvement (P <.001), and/or systemic B symptoms including fever,
night sweats, and/or weight loss (P =.05). Median survival did not
differ between marrow-positive and marrow-negative groups. On
multivariate analysis, factors associated with decreased survival of
marrow-positive patients included greater than 50% involvement (P
=.002), systemic B symptoms (P =.008), and high-grade histologic type (P
=.035). Marrow involvement in ARL correlates with small noncleaved
pathology, thrombocytopenia lower than 100 000 mm(3), high LDH, and
lymphomatous involvement of the CSF. Survival is statistically shorter
in patients with greater than 50% marrow involvement, high-grade
pathology, and/or systemic B symptoms.
7
UI - 11704827
AU - Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack
TI -
ER; Barber GN; Harrington WJ Jr
Induction of a TRAIL-mediated suicide program by interferon alpha in
primary effusion lymphoma.
SO - Oncogene 2001 Oct 25;20(48):7029-40
AD - Department of Medicine, University of Miami School of Medicine, Miami,
Florida, FL 33136, USA.
Gammaherpes viruses are often detected in lymphomas arising in
immunocompromised patients. We have found that Azidothymidine (AZT)
alone induces apoptosis in Epstein Barr Virus (EBV) positive Burkitt's
lymphoma (BL) cells but requires interferon alpha (IFN-alpha) to induce
apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion
Lymphomas (PEL). Our analysis of a series of AIDS lymphomas revealed
that IFN-alpha selectively induced very high levels of the Death
Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas
little or no induction was observed in primary EBV+ AIDS lymphomas and
EBV-Burkitt's lines. AZT and IFN-alpha mediated apoptosis in PEL was
blocked by stable overexpression of dominant negative Fas Associated
Death Domain (FADD), decoy receptor 2 (DcR2), soluble TRAIL receptor
fusion proteins (DR-4 and DR-5) and thymidine. Trimeric TRAIL (in place
of IFN-alpha) similarly synergized with AZT to induce apoptosis in HHV-8
positive PEL cells. This is the first demonstration that IFN-alpha
induces functional TRAIL in a malignancy that can be exploited to effect
a suicide program. This novel antiviral approach to Primary Effusion
lymphomas is targeted and may represent a highly effective and
relatively non-toxic therapy.
8
UI - 11378571
AU - Tsimberidou AM; Sarris AH; Medeiros LJ; Mesina O; Rodriguez MA;
TI -
Hagemeister FB; Romaguera J; Pro B; McLaughlin P; Dang N; Cabanillas F
Hodgkin's disease in patients infected with human immunodeficiency
virus: frequency, presentation and clinical outcome.
SO - Leuk Lymphoma 2001 May;41(5-6):535-44
AD - Department of Lymphoma and Myeloma, The University of Texas M.D.
Anderson Cancer Center Houston, Texas 77030, USA.
We report the frequency, presenting characteristics, progression-free
survival, event-free survival, overall survival and AIDS-free survival
of patients with previously untreated Hodgkin's disease (HD) in the
setting of infection by human immunodeficiency virus (HIV). To
accomplish this we retrospectively reviewed all untreated patients
presenting to the University of Texas M.D. Anderson Cancer Center
available records were reviewed to determine presentation, clinical
characteristics, treatment outcome, progression-free survival and
overall survival. We identified 887 patients with HD and 3,500 with
Non-Hodgkin's Lymphoma (NHL). The ratio of NHL to HD in HIV-negative
versus HIV-positive patients was 3.9 versus 6.9, respectively. There
were 14 HIV-positive patients with HD and 97 with NHL. The median age of
the HIV-positive HD patients was 33 years, and 13 were male. Three
patients had Acquired Immune Deficiency syndrome (AIDS) at the time of
HD diagnosis, and seven had B-symptoms. Ann Arbor stage was I in one, II
in three, III in four and IV in six patients. Mixed cellularity
histology was seen in eight, bone marrow involvement in five and
extranodal disease in seven patients. Four patients had elevated serum
lactate dehydrogenase, three low serum albumin, and nine elevated serum
beta2-microglobulin, The median CD4 count was 160/microl. Eleven
patients received ABVD or equivalent regimens, followed by radiotherapy
in five. One patient was treated with COPP and radiotherapy, one with
NOVP and radiotherapy and one only with radiotherapy. All patients
received some antiretroviral therapy, but it was variable over the
years. With a median follow-up of 64 months for survivors, the projected
5-year progression-free survival was 64%, event-free survival 45%,
overall survival 54% and AIDS-free survival 45%. Six patients died of
complications arising from HIV infection, including one patient who had
preexisting AIDS at HD presentation. Two patients died of HD, without
developing other conditions diagnostic of AIDS. We conclude that in our
referral patient population HIV infection is associated with
preferential development of NHL rather than HD, which appears curable
with standard treatment regimens. Since HIV-related deaths exceed those
caused by HD, future investigation should focus on integration of
chemotherapy and highly active antiretroviral therapy.
9
UI - 11642021
AU - Rigolet A; Bossi P; Caumes E; Agher R; Zeller V; Katlama C; Bricaire F
TI -
[Epidemiological features and incidence trends of primary cerebral
lymphomas observed in 80 HIV-infected patients from 1983 to 1999]
SO - Pathol Biol (Paris) 2001 Sep;49(7):572-5
AD - Services de maladies infectieuses et tropicales, hopital
Pitie-Salpetriere, 47-83, boulevard de l'Hopital, 75651 Paris, France.
OBJECTIVE: To describe the epidemiological characteristics of primary
central nervous system lymphoma (PCNSL) and the evolution of the
incidence of this lymphoma in HIV-infected patients with a more than
17-year follow-up. RESULTS: Eighty cases of PCNSL were analyzed from a
data base of 2,263 AIDS subjects followed from 1983 to 1999 (3.5% of the
patients with AIDS). At the time of diagnosis, PCNSL was the first AIDS
defining event in 36% of the cases, median CD4 count was 9/mm3 (0-134);
82% of the patients were given antiretroviral therapy (HAART = 0). Only
eight cases of PCNSL were observed after 1996 (median HIV RNA level:
250,000 copies/mL (24,000-1,500,000)). The incidence was 39 per 100
patients-year in 1991 and decreased to 1.9 in 1999. At the end of the
study, 78 patients had died (98%). The median survival was one month
before 1996 ([0-27], n = 72), and was ten months after ([0-44], n = 8).
Two patients were still alive 38 and 44 months after diagnosis. After
1996, survival was increased in patients with good response to
antiretroviral treatment and in patients with high CD4 count at the
moment of diagnosis. CONCLUSION: After the introduction of HAART (1996),
the incidence of PCNSL has decreased drastically and survival was
increased.
10
UI - 11569325
AU - Geraci AP; Simpson DM
TI -
Neurological manifestations of HIV-1 infection in the HAART era.
SO - Compr Ther 2001 Fall;27(3):232-41
AD - Neuro-AIDS Research Program, Departments of Neurology and Clinical
Neurophysiology, Mount Sinai Medical Center, New York, NY 10029, USA.
Neurologic complications in patients with AIDS are diverse and include
opportunistic infections and lymphoma, as well as HIV-related peripheral
neuropathy, myelopathy, and dementia. Improved prophylaxis and
antiretroviral therapies have modified the approach to neurologic
disease in the setting of AIDS.
11
UI - 11519566
AU - Thurnher MM; Rieger A; Kleibl-Popov C; Schindler E
TI -
Malignant lymphoma of the cranial vault in an HIV-positive patient:
imaging findings.
SO - Eur Radiol 2001;11(8):1506-9
AD - Department of Radiology, University of Vienna, Austria.
majda.thurnher@univie.ac.at
We describe the CT and MR imaging findings in an HIV-positive patient
with malignant non-Hodgkin's lymphoma of the cranial vault, a rare site
for lymphoma involvement. Autopsy revealed lymphomatous bone lesions,
lymphoma in the epidural space, and a large necrotic lymphoma in the
soft tissue of the skull.
12
UI - 11739198
AU - Krishnan A; Molina A; Zaia J; Nademanee A; Kogut N; Rosenthal J; Woo D;
TI -
Forman SJ
Autologous stem cell transplantation for HIV-associated lymphoma.
SO - Blood 2001 Dec 15;98(13):3857-9
AD - Division of Hematology and Bone Marrow Transplantation, City of Hope
Medical Center, Duarte, California 91010, USA. akrishnan@coh.org
Is peripheral stem cell mobilization followed by autologous stem cell
transplantation (ASCT) feasible in patients with human immunodeficiency
virus (HIV)- associated lymphoma (HIV-L)? Studies have demonstrated
that, in the HIV- negative (HIV(-)) setting, ASCT may improve
lymphoma-free survival in high-risk non-Hodgkin lymphoma (NHL) or
relapsed Hodgkin disease (HD) and NHL. Given the poor prognosis of HIV-L
with conventional chemotherapy, this dose-intensive approach was
explored. Nine patients with HIV-HD or NHL mobilized a median of 10.6 x
10(6) CD34(+) cells/kg and engrafted after ASCT. CD4 counts recovered to
pretransplantation levels and HIV viral loads were controlled in
patients compliant with antiretroviral therapy. Seven of 9 patients
remain in remission from their lymphoma at a median of 19 months after
transplantation. Thus, patients with HIV-L on antiretroviral therapy can
engraft following ASCT. Prolonged lymphoma remissions, without
significant compromise of immune function, can be seen, suggesting that
ASCT can be used in selected patients with HIV-L.
13
UI - 11747850
AU - Gabarre J; Raphael M; Lepage E; Martin A; Oksenhendler E; Xerri L;
TI -
Tulliez M; Audouin J; Costello R; Golfier JB; Schlaifer D; Hequet O;
Azar N; Katlama C; Gisselbrecht C; Groupe d'Etude des Lymphomes de
l'Adulte (GELA)
Human immunodeficiency virus-related lymphoma: relation between clinical
features and histologic subtypes.
SO - Am J Med 2001 Dec 15;111(9):704-11
AD - Service d'Hematologie Clinique, Hopital Pitie-Salpetriere, Paris,
France.
PURPOSE: Non-Hodgkin's lymphoma occurs frequently in patients with human
immunodeficiency virus (HIV) infection and acquired immunodeficiency
syndrome (AIDS). We determined the association between the clinical and
histologic features of HIV-related lymphoma. SUBJECTS AND METHODS: We
reviewed the medical records of 291 patients with noncerebral
HIV-related lymphoma who had been treated in multicenter trials
coordinated by the Groupe d'Etude des Lymphomes de l'Adulte between 1988
and 1997. This study was performed mainly before the availability of
combination antiretroviral therapy. RESULTS: The main histologic
subtypes were centroblastic lymphoma in 131 patients (45%),
immunoblastic lymphoma in 39 patients (13%), and Burkitt's lymphoma
(including the classical form and the variant with plasmacytic
differentiation) in 115 patients (40%). Burkitt's lymphoma was the most
aggressive form, whereas immunoblastic lymphoma occurred in severely
immunodeficient patients. Two-year survival after enrollment was 15% in
immunoblastic lymphoma, 32% in Burkitt's lymphoma, and 31% in
centroblastic lymphoma (P = 0.006), but multivariate analysis did not
confirm the independent prognostic value of histologic subtype. Instead,
five independent pretreatment factors increased the risk of mortality:
age 40 years or older [relative risk (RR) = 1.5; 95% confidence interval
(CI), 1.1 to 2.1; P = 0.005], elevated serum lactate dehydrogenase level
(RR = 1.5; 95% CI, 1.1 to 2.1; P = 0.02), having a diagnosis of AIDS
before lymphoma (RR = 1.8; 95% CI, 1.2 to 2.6; P = 0.006), CD4(+) cell
count less than 100 x 10(6)/L (RR = 1.8; 95% CI, 1.3 to 2.6; P =
0.0004), and impaired performance status (RR = 2.4; 95% CI, 1.7 to 3.4;
P <0.0001). CONCLUSION: Several pretreatment characteristics of
HIV-related lymphoma were linked to the histologic form, but HIV disease
parameters other than those of lymphoma were the main determinants of
outcome, so the histologic features of the lymphoma were not associated
with prognosis.
14
UI - 11770603
AU - Gates EJ; Diaz-Arrastia C; DiMaio T; Maiman MA
TI -
Non-Hodgkin lymphoma of the endometrium in human immunodeficiency virus
infection.
SO - Obstet Gynecol 1997 Oct;90(4 Pt 2):697-9
AD - Department of Obstetrics and Gynecology, State University of New York
Health Science Center at Brooklyn, USA.
BACKGROUND: Non-Hodgkin lymphoma has become a common malignancy in
patients infected with the human immunodeficiency virus (HIV), being
classified as an acquired immunodeficiency syndrome-defining malignancy.
The female genital tract is involved usually with non-Hodgkin lymphoma
as part of disseminated disease. It is extremely rare for this tumor to
originate in the female reproductive tract, especially in the
endometrium. CASE: An HIV-positive woman underwent a total abdominal
hysterectomy and bilateral salpingo-oophorectomy for intractable
menometorrhagia and resultant anemia thought to be secondary to uterine
leiomyoma. The histologic diagnosis was high-grade, immunoblastic,
non-Hodgkin lymphoma with plasmacytoid features originating in the
endometrium. CONCLUSION: This unusual presentation obligates the
clinician to include non-Hodgkin lymphoma in the differential diagnosis
when evaluating HIV-positive patients with abnormal uterine bleeding
that cannot be explained after thorough evaluation.
15
UI - 11768867
AU - Anonymous
TI -
AIDS and lymphoma.
SO - Treatmentupdate 2001 Oct;13(6):2-3
16
UI - 11768868
AU - Anonymous
TI -
Encouraging news on lymphoma from France.
SO - Treatmentupdate 2001 Oct;13(6):3-4
17
UI - 11768869
AU - Anonymous
TI -
Chemo and HAART extend survival with lymphoma.
SO - Treatmentupdate 2001 Oct;13(6):4-6
18
UI - 11768872
AU - Anonymous
TI -
Looking at soluble CD23 levels to predict lymphoma.
SO - Treatmentupdate 2001 Oct;13(6):7-8
As we noted in our first article on lymphoma, there isn't any quick and
simple test to diagnose or predict which PHAs will develop this cancer.
Nor are there any symptoms that specifically occur from having lymphoma.
To try to remedy the situation, researchers in Italy have been
monitoring levels of the a protein called soluble CD23 (sCD23) in the
blood and fluid surrounding the brain--cerebrospinal fluid (CSF). They
have found higher-than-normal levels of sCD23 in the CSF of PHAs who
have brain lymphoma.
19
UI - 7729949
AU - Polito P; Cilia AM; Gloghini A; Cozzi M; Perin T; De Paoli P; Gaidano G;
TI -
Carbone A
High frequency of EBV association with non-random abnormalities of the
chromosome region 1q21-25 in AIDS-related Burkitt's lymphoma-derived
cell lines.
SO - Int J Cancer 1995 May 4;61(3):370-4
AD - Division of Pathology, Istituto Nazionale di Ricovero e Cura a Carattere
Scientifico, Aviano, Italy.
Chromosome 1q abnormalities represent the second most frequent
cytogenetic lesion of Burkitt lymphoma (BL) and acute lymphoblastic
leukemia (ALL)-L3. The most frequent change is partial duplication of
the long arm of chromosome 1, involving variable bands but consistently
including 1q23. Among AIDS-related BL similar chromosome 1q
abnormalities have also been found. We have now characterized in detail
the chromosome 1q abnormalities of 4 AIDS-BL cell lines and compared
them to other molecular features of the tumor clone, namely infection by
Epstein Barr virus (EBV). Immunophenotypic characteristics were also
assessed by conventional in situ immunocytochemical and flow cytometric
procedures. The B-cell origin of all cell lines was demonstrated by the
expression of B-cell-restricted markers (e.g., CD19). Analysis of Ig
light chains confirmed their monoclonal nature. The t(8;14) was present
in 3 of the 4 lines, whereas variant translocation t(8;22) was detected
in the remaining cell line. Additional chromosomal changes were found in
all cases, with chromosome 1 being involved in all. Structural changes
encompassed in each case the 1q21-25 bands, in either duplication or
partial trisomy. EBER ISH studies identified EBV association in 3 of the
4 AIDS-BL cell lines in contrast to previous studies of BL of
immunocompetent individuals. Our findings of a high frequency of
chromosome 1q abnormalities in EBV-infected AIDS-related BL cell lines
demonstrate that such chromosomal abnormality and EBV positivity are not
mutually exclusive and are possibly independent factors, whereas their
close association in AIDS may be related to the immunodeficiency.
20
UI - 8759621
AU - Polito P; Canzonieri V; Cilia AM; Gloghini A; Gaidano G; Carbone A
TI -
Structural abnormality of 1q in an AIDS-related body-cavity-based
lymphoma.
SO - Int J Cancer 1996 Aug 7;67(4):588-90
21
UI - 8780557
AU - Polito P; Canzonieri V; Cilia AM; Gloghini A; Carbone A; Gaidano G
TI -
Centromeric instability of chromosome 1 resulting in multibranched
chromosomes, telomeric fusions, and "jumping translocations" of 1q in a
human immunodeficiency virus-related non-Hodgkin's lymphoma.
SO - Cancer 1996 Sep 1;78(5):1142-4
22
UI - 11684931
AU - Hoffmann C; Tabrizian S; Wolf E; Eggers C; Stoehr A; Plettenberg A; Buhk
TI -
T; Stellbrink HJ; Horst HA; Jager H; Rosenkranz T
Survival of AIDS patients with primary central nervous system lymphoma
is dramatically improved by HAART-induced immune recovery.
SO - AIDS 2001 Nov 9;15(16):2119-27
AD - Curatorium for Immunedeficiency, Munich, Germany.
OBJECTIVE: To evaluate the impact of immune recovery induced by highly
active antiretroviral therapy (HAART) on the survival of AIDS patients
with primary central nervous system lymphoma (PCNSL). METHODS: In a
multicentric retrospective analysis, 29 HIV-infected patients with
histologically confirmed PCNSL were identified. To evaluate median
survival, Kaplan-Meier statistics were used. To explore the effects of
different variables on survival, a Weibull accelerated failure time
regression analysis was performed. RESULTS: Median age at manifestation
of PCNSL was 39.1 years and median CD4 cell count was 11 x 10(6)
cells/l. Seventy per cent of the patients had had a prior AIDS-defining
illness. Cranial radiation (CR) was given to 12 out of 29 patients. Six
patients were treated with HAART. Survival time of these patients and of
the patients treated with CR alone differed significantly from those
receiving neither CR nor HAART (median Kaplan-Meier survival estimate:
1093, 132, and 33 days, respectively). In the multivariate regression
model, HAART and CR were identified as the only variables independently
associated with prolonged survival. HAART versus no HAART and CR versus
no CR increased the time to event by a factor of 6.1 (95% confidence
interval, 2.4-16.0; P = 0.0002) and 3.1 (95% confidence interval,
1.5-6.3; P = 0.002), respectively. Four out of six patients on HAART
showed a marked immune recovery and survived for more than 1.5 years,
with two patients still alive. CONCLUSION: Data from this cohort
indicate that immune recovery induced by HAART leads to dramatic
improvement in survival of patients with AIDS-associated PCNSL. These
findings may have important implications for future treatment
strategies.
23
UI - 11570267
AU - Hong S; Krafft AE
TI -
Primary effusion lymphoma with herpesvirus 8 DNA in patients coinfected
with HIV and hepatitis C virus: a report of 2 cases.
SO - AIDS Read 2001 Aug;11(8):418-22
AD - Department of Pathology, College of Medicine, Howard University
Hospital, Washington, DC, USA.
The primary effusion lymphoma (PEL), commonly described in patients with
AIDS, is a unique subset of diffuse large cell lymphoma in which the
malignant lymphocytes proliferate exclusively in serous cavities. The
cytologic, immunophenotypic, and molecular features of PEL are presented
from findings of 2 patients coinfected with HIV and hepatitis C virus
who presented with abdominal pain. Abdominal radiography in both
patients displayed marked peritoneal effusions. Cytomorphologic
examination of peritoneal fluid revealed a malignant lymphoma in both.
Their immunophenotypic expression was CD30 (Ki-1) and epithelial
membrane antigen. Molecular analysis demonstrated human herpesvirus 8
DNA in both patients and bcl-2 oncogene rearrangement within the major
breakpoint region of t(14;18) chromosome translocation in Case B only.
Clinical correlation supports the current concept that PEL represents a
primary HIV/AIDS-related lymphoma in effusion. Cytomorphologic
examination of body cavity fluid serves as a tool for the initial
diagnosis of PEL.
24
UI - 11721496
AU - Calza L; Manfredi R; Chiodo F
TI -
[Burkitt's lymphoma with atypical cutaneous lesion in an HIV-infected
patient]
SO - Presse Med 2001 Oct 27;30(31 Pt 1):1552-3
25
UI - 11770227
AU - Colebunders R; Dohmen S; Van de Velde A; Pelgrom J; Hermans P
TI -
Burkitt's lymphoma shortly after an acute HIV infection, treated with
highly active retroviral treatment.
SO - Acta Clin Belg 2001 Sep-Oct;56(5):321-2
26
UI - 11757018
AU - Mayorca A; Hazime N; Dekeister C; Paoli JR
TI -
Necrotizing stomatitis after radiotherapy in a patient with AIDS: case
report.
SO - J Oral Maxillofac Surg 2002 Jan;60(1):100-1
AD - Oral and Maxillofacial Surgery Department, Hopital Rangueil, Toulouse,
France.
27
UI - 11499405
AU - Dronda F; Patier JL; Armas M; Bellas C
TI -
[27-year old male with AIDS and fever, lymphadenopathies, and immature
cells in peripheral blood of recent appearance]
SO - Rev Clin Esp 2001 Jun;201(6):352-61
AD - Servicio de Enfermedades Infecciosas, Hospital Ramon y Cajal, Madrid.
28
UI - 11511024
AU - Kersten MJ; Van Oers RH
TI -
Management of AIDS-related non-Hodgkin's lymphomas.
SO - Drugs 2001;61(9):1301-15
AD - Department of Medical Oncology, Netherlands Cancer Institute/Antoni van
Leeuwenhoekhuis, Amsterdam. kersten@nki.nl
The incidence of non-Hodgkin's lymphoma in individuals infected with HIV
is approximately 60- to 100-fold increased over the general population.
The majority of patients with AIDS-related lymphoma (ARL) present with
stage III-IV disease and with B-symptoms. They often have multiple
extranodal localisations, with a high incidence of central nervous
system involvement. Histologically, most tumours are either diffuse
large cell lymphomas or Burkitt lymphomas. Several factors, such as
disrupted immune surveillance, Epstein-Barr virus infection, chronic
antigenic stimulation, cytokine dysregulation and the acquisition of
genetic lesions, are thought to contribute to the pathogenesis. Patients
with ARL have a poor prognosis: overall survival ranges from 1.5 to 18
months. The most important adverse prognostic factors are poor
performance status, a low CD4+ cell count and a history of opportunistic
infections. Results of treatment with polychemotherapy compare
unfavourably to results in patients without HIV infection. Since the
advent of highly active antiretroviral therapy (HAART), there appears to
be a decrease in the incidence of ARL. In addition, the use of HAART in
combination with chemotherapy and the use of new treatment modalities
may improve the outcome of this disease.
29
UI - 11744828
AU - Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
TI -
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy
for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
SO - J Acquir Immune Defic Syndr 2001 Dec 15;28(5):416-21
AD - Department of Medicine, University of Southern California Keck School of
Medicine, Los Angeles, California, USA.
No effective salvage regimen has been defined for patients with
AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) who do not respond to
first-line chemotherapy that contains anthracycline. Combined
dexamethasone, cytosine arabinoside, and cisplatin (DHAP) and etoposide,
methylprednisolone, cytosine arabinoside, and cisplatin (ESHAP) have
shown good response rates in HIV-negative patients with relapsed
lymphomas. We retrospectively analyzed patients with refractory or
relapsed AIDS-NHL who had been treated with either DHAP or ESHAP to
evaluate the feasibility and efficacy of these regimens. Twenty-six
patients with refractory or relapsed AIDS-NHL were treated between 1990
and 1999 either with DHAP ( n = 13) or with ESHAP ( n = 13). Only 1
patient from each group (8%) had achieved complete remission with any
previous therapy, and most had progressive disease after the regimen
immediately preceding DHAP or ESHAP. In the ESHAP group, 4 patients
(31%) achieved complete remission (CR) and 3 patients (23%) attained
partial remission (PR) for an overall response rate of 54%. The median
survival was 7.1 months (range, 1-58.9+ months) from the time ESHAP was
begun. Among the 3 patients with primary refractory lymphoma, there was
1 CR, 1 PR, and one patient with stable disease. In contrast, only 1 PR
(7%) was observed with DHAP; the median survival was 3 months.
Myelosuppression was the most significant toxicity with grade 4
neutropenia occurring in all who received ESHAP and in 54% of patients
treated with DHAP. Neutropenic fever occurred in 8 (62%) ESHAP-treated
and 6 (46%) DHAP-treated patients. Although hematologic toxicity is
profound, ESHAP appears to be an active salvage regimen for patients
with relapsed or refractory AIDS-NHL.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
